2023-09-29 09:52:00

3 Stocks to Buy if You're Afraid to Buy Stocks

Logo Nasdaq
Nasdaq
By The Motley Fool

It's scary out there. And by there I mean the stock market.

All of the major market indexes have entered bear market territory. Concerns are mounting that a full-blown recession could be on the way. Inflation remains frustratingly high.

Fear seems to be the prevailing emotion among many investors. That's understandable. However, you don't have to be trembling in your boots about every stock. Here are three stocks to buy if you're afraid of buying stocks.

1. Vertex Pharmaceuticals

The stock market's huge downturn so far this year hasn't impacted Vertex Pharmaceuticals (NASDAQ: VRTX) in the least. Shares of the big biotech have soared close to 30% year to date. Vertex could move even higher.

AD
AD

Inflation and the threat of a recession simply don't matter much to Vertex. The company markets the only drugs that treat the underlying cause of cystic fibrosis (CF). Its nearest rivals are years away from having even the possibility of launching competing therapies. The bottom line is that Vertex's CF drugs will continue raking in billions of dollars regardless of what happens with the stock market or the economy.

Even better, Vertex could have a new product beyond CF on the market relatively soon. The company and its partner, CRISPR Therapeutics, plan to begin filing for regulatory approvals of exa-cel in treating sickle cell disease and transfusion-dependent beta-thalassemia within the next few months. Exa-cel could become the first gene-editing therapy to reach the market.

Continue read on nasdaq.com

AD
Logo The Motley Fool
MarketsBy Newsfeedback@Fool Com (Keith Speights)2023-09-29 09:52:00
It's scary out there. And by there I mean the stock market. All of the major market indexes have entered bear market territory. Concerns are mounting that a...

Logo Nasdaq
MarketsBy Zacks2024-09-06 14:34:00
CRISPR Therapeutics CRSP lead pipeline candidate is exagamglogene autotemcel (exa-cel, formerly CTX001), an investigational ex-vivo CRISPR gene-edited...

Logo The Motley Fool
MarketsBy Newsfeedback@Fool Com (Eric Volkman)2024-09-27 21:52:04
What happened Vertex Pharmaceuticals ( VRTX 2.88%), a commercial-stage biotech specializing in treatments for cystic fibrosis, saw its share price rise on...

Logo Nasdaq
Business / FinanceBy The Motley Fool2024-09-27 21:52:04
What happened Vertex Pharmaceuticals (NASDAQ: VRTX), a commercial-stage biotech specializing in treatments for cystic fibrosis, saw its share price rise on...

Logo Nasdaq
MarketsBy Zacks2023-09-28 17:17:00
Vertex Pharmaceuticals VRTX secured permission from the FDA to initiate a rolling biologics license application (BLA) submission for its ex-vivo gene-therapy...

Logo Nasdaq
MarketsBy The Motley Fool2024-09-10 14:45:00
The biotech sector has had a challenging year so far. The SPDR S&P Biotech ETF is still down more than 26%, and the iShares Biotechnology ETF is down...

Logo The Motley Fool
MarketsBy Newsfeedback@Fool Com (Jim Halley)2024-09-10 14:45:00
The biotech sector has had a challenging year so far. The SPDR S&P Biotech ETF is still down more than 26%, and the iShares Biotechnology ETF is down...

Logo Benzinga
MarketsBy Adam Eckert2024-09-27 12:55:54
CRISPR Therapeutics AG CRSP shares are trading higher Tuesday after the company and Vertex Pharmaceuticals Inc VRTX announcedtheU.S. Food and Drug...

Logo Benzinga
MarketsBy Vandana Singh2023-09-28 16:39:11
MaxCyte Inc MXCT has signed a strategic platform license with Vertex Pharmaceuticals Incorporated VRTX. Under the terms of the agreement, Vertex obtains...

Logo The Motley Fool
MarketsBy Newsfeedback@Fool Com (Alex Carchidi)2023-09-28 10:20:00
There's a lot of uncertainty in the air right now. Between rumors of a recession, rising interest rates, and inflation, it's tough to find stocks that you're...

Logo InvestorPlace
MarketsBy William White2024-09-27 14:53:25
Source: rafapress / Shutterstock.com Crispr Therapeutics (NASDAQ: CRSP ) stock is gaining on Tuesday after the FDA granted exagamglogene autotemcel (exa-cel)...

Logo The Motley Fool
MarketsBy Newsfeedback@Fool Com (Keith Speights)2024-09-24 09:52:00
This story might sound familiar: Inflation is high. In response, the Federal Reserve raises interest rates multiple times. The stock market sinks....

Logo Nasdaq
MarketsBy The Motley Fool2024-09-24 09:52:00
This story might sound familiar: Inflation is high. In response, the Federal Reserve raises interest rates multiple times. The stock market sinks....

Logo Nasdaq
MarketsBy The Motley Fool2024-09-19 14:15:00
Portfolio manager Cathie Wood is known for having an aggressive appetite for risk when it comes to the investments she makes in her exchange-traded fund, the...

Logo The Motley Fool
MarketsBy Newsfeedback@Fool Com (Prosper Junior Bakiny)2023-09-28 12:00:00
Several biotech stocks have outperformed the struggling market this year. This list includes Vertex Pharmaceuticals ( VRTX 2.88%), Exelixis ( EXEL 0.06%),...

Logo Nasdaq
Business / FinanceBy The Motley Fool2023-09-28 12:00:00
Several biotech stocks have outperformed the struggling market this year. This list includes Vertex Pharmaceuticals (NASDAQ: VRTX), Exelixis (NASDAQ: EXEL),...

Logo The Motley Fool
MarketsBy Newsfeedback@Fool Com (Alex Carchidi)2024-09-22 14:00:00
Usually, a bit of hesitation is good when you're investing. Taking a moment to research a company and understand its valuation, its weak points, and its...

Logo Nasdaq
MarketsBy The Motley Fool2024-09-04 14:36:00
The biotech industry is heavily regulated by the federal government and its science watchdog, the Food and Drug Administration (FDA). As a consequence,...

Logo The Motley Fool
MarketsBy Newsfeedback@Fool Com (Taylor Carmichael)2024-09-04 14:36:00
The biotech industry is heavily regulated by the federal government and its science watchdog, the Food and Drug Administration (FDA). As a consequence,...

Logo Nasdaq
Business / FinanceBy The Motley Fool2024-09-22 14:00:00
Usually, a bit of hesitation is good when you're investing. Taking a moment to research a company and understand its valuation, its weak points, and its...